Pharmaceutical
Excerpt from the Press Release: NORWOOD, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) (“Corbus” or the “Company”), announced that data from its US and UK conducted first-in-human dose escalation clinical study (“Western study”) of CRB-701 (SYS6002) is being presented today at the 2025 American Society of Clinical Oncology Genitourinary Cancers…
Read More
Excerpt from the Press Release: Boston (February 6, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific patient selection technology—the Drug Response Predictor (DRP®)—today announced plans for the next step in advancing…
Read More
Excerpt from the Press Release: MANSFIELD, MA – Last month, Aclarity, a leader in PFAS removal, officially completed the move from Mansfield Bio-Incubator to their new headquarters in Medway. September 2022, the time when Aclarity became Mansfield Bio-Incubator’s member with less than five lab-based employees and taking up a bench in the shared space, seems…
Read More
Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy threshold not achieved to support continued development by Foghorn alone Company to prioritize investment into proprietary pipeline and Lilly collaboration programs, including the clinical-stage selective SMARCA2 (BRM)…
Read More
Collaboration utilizes PeriNess’ expertise in clinical development of human recombinant DNase and bolsters efforts towards clinical proof-of-concept studies in multiple indications Excerpt from the Press Release: FRAMINGHAM, MA / ACCESSWIRE / December 5, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to…
Read More
We are thrilled to announce this significant milestone in the clinical investigation of ABI-110″ said Shawn Liu, Ph.D., Chief Executive Officer of Avirmax Biopharma Inc. “ABI-110 has the potential to revolutionize the treatment landscape for Wet AMD and PCV.” Excerpt from the Press Release: HAYWARD, Calif., Nov. 21, 2024 /PRNewswire/ — Avirmax Biopharma, Inc., a leader in the…
Read More
Excerpt from the Press Release: HBI-3000 Aims to Fill Critical Gaps in Atrial Fibrillation Care; Key Data to be Presented at the American Heart Association Annual Meeting SAN DIEGO, Nov. 14, 2024 /PRNewswire/ — HUYABIO International today announced the presentation of new patient data for HBI-3000, an antiarrhythmic drug (AAD) with a unique protective profile for the treatment of atrial fibrillation (AF), one of the most common and serious heart conditions worldwide. This promising drug will be highlighted in a moderated poster presentation in the session entitled “The Return of Antiarrhythmic Drug Therapy: A New Age…
Read More
Data supporting the potential for innovative combinations like HBI-8000 and nivolumab to reshape the future of melanoma treatment will be presented at the Society for Immunotherapy of Cancer Annual Meeting Excerpt from the Press Release: SAN DIEGO, Nov. 8, 2024 /PRNewswire/ — HUYABIO International today announced it will present the final analysis of data from a phase…
Read More
Treatment with STK-012 monotherapy demonstrates dose-dependent induction of pro-inflammatory cytokines and selective proliferation of antigen-activated T cells, along with significant expansion of TCR clonality Company will also present new preclinical and GLP toxicology data on STK-026, its biased IL-12 partial agonist also designed for preferential activity on antigen-activated T cells Excerpt from the Press Release:…
Read More
Late-breaking presentation highlights the pTau217 assay as an effective and efficient tool to screen participants for ALTITUDE-AD that reduces unnecessary amyloid PET scans and lumbar puncture procedures for those who are not eligible Excerpt from the Press Release: NEWTON, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company…
Read More